Nice | Ticagrelor for the treatment of acute coronary syndrome ACS

4th November 2011 by Louise Hudman

Ticagrelor is a PO drug which inhibits platelet aggregation. In combination with aspirin it is more effective than clopidogrel + aspirin at reducing the endpoint of MI or death from vascular events.

It will be started by secondary care and continued by cardiologists, so we shouldn’t really have to initiate it.

It will be started in patients who’ve had a STEMI where primary percutaneous coronary intervention (PCI) is considered and also in patients with a NSTEMI who have certain other risk factors.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"Thank you for the service you have provided while I have been a member over the last few years. I have found the website and sessional magazine very helpful during my time as a locum."

Dr Rachael Scott

Dr Rachael Scott

See the full list of features within our NASGP membership plans

Membership